BioSpace News Archive

ANP Technologies Inc. (ANP) and Fulgent Pharma LLC through their partner Moffitt Cancer Center have successfully licensed the rights to develop a novel targeted therapy in the area of leukemia to Celgene (CELG), now Bristol Myers Squibb (BMY), a landmark deal that leverages ANP’s nanotherapeutic platform technology.

CEL-SCI Corporation (NYSE American: CVM) announced today its Chief Executive Officer Geert Kersten will attend two upcoming healthcare investor conferences in San Francisco and New York.

Aligos Therapeutics, Inc., a preclinical stage biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), today announced the closing of an oversubscribed $125M Series B equity financing round led by Wellington Management Company and a global investment management firm

TauC3 Biologics Limited, a newly established privately held British biopharmaceutical company developing an innovative immunotherapy with the demonstrated potential to prevent the spread of tau pathology in the brain, today announced the appointments of Andrew J. Heath, MD, PhD as Non-Executive Chairman of its Board of Directors and Shafique Virani, MD as Non-Executive Director.

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced a financing and co-development collaboration with SFJ Pharmaceuticals to support the development of PB2452, a reversal agent for the antiplatelet therapy ticagrelor.

Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Fluvoxamine Maleate Tablets in 25 mg, 50 mg and 100 mg strengths.

The strategic collaboration will see the expanded development of the wearable smart technology MOTIONSENSE™ and the data analytics of ORTHOLOGIQ® to improve patient care in orthopedic surgery

The patents cover Illumina’s proprietary sequencing-by-synthesis chemistry.

A consortium of key academic and global seed company leaders from the USA, Canada, Europe, and Israel are announcing the completion of multiple rapeseed/canola reference genomes.

More than 320 Health Systems Across the Country Are Now Using RxRevu’s Real-Time Benefit Tools to View Patient Coverage Information and Recommend Prescription Alternatives at the Point of Care [10-January-2020] DENVER , Jan. 10, 2020 /PRNewswire/ -- RxRevu achieved unprecedented growth in 2019, advancing its position as the leader in Prescription Decision Support. In